To some observers, Vertex Pharmaceuticals Inc. would seem to have the cystic fibrosis (CF) market wrapped up. With Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor) already market-leading CF drugs, the Boston-based firm wowed investors and analysts this month with prospects for next-generation correctors, VX-659 and VX-445, which are moving into phase III development as part of separate triple-combination regimens.